INVESTOR RELATIONS

* For additional information about share price and latest announcements please review HeraMED’s page on the ASX platform View Page

  • Correction to Appendix 4C14/08/2019View
  • HeraMED enters the German market with initial PO secured12/08/2019View
  • June Quarterly Activities Report & Appendix 4C31/07/2019View
  • HeraCARE Investor Presentation July 201922/07/2019View
  • HeraCARE PRO Integrated into Hapvidas Hospital Systems01/07/2019View
  • HeraBEAT Australian B2C launch underway19/06/2019View
  • Appendix 3B14/06/2019View
  • Appendix 3B06/06/2019View
  • Appendix 3B03/06/2019View
  • Release of Securities from Escrow31/05/2019View
  • Results of Annual General Meeting29/05/2019View
  • Annual General Meeting Venue Room Update24/05/2019View
  • Dr Friedman joins HeraMED advisory board20/05/2019View
  • HeraMED to launch HeraBEAT in Mexico15/05/2019View
  • Company Presentation May 201914/05/2019View
  • Release of Securities from Escrow09/05/2019View
  • HeraMED Expands European Distribution Network Clarification08/05/2019View
  • HeraMED Expands European Distribution Network08/05/2019View
  • HeraMED begins FDA Approval Process for HeraBEAT29/04/2019View
  • Notice of Annual General Meeting and Proxy Form26/04/2019View
  • March Quarterly Activity Report & Appendix 4C26/04/2019View
  • Meerkats Partners for HeraBEATs Australian B2C Launch16/04/2019View
  • HeraMED launches HeraBEAT in the United Kingdom11/04/2019View
  • Response to ASX Query – Annual Report as at 31/12/1808/04/2019View
  • Addendum to Annual Report05/04/2019View
  • Appendix 4G29/03/2019View
  • Annual Report29/03/2019View
  • Orion Artificial Intelligence Presentation26/03/2019View
  • Dr Arturo Weschler MD Appointed to Lead Orion AI Operations26/03/2019View
  • Quasar Manufacturing Agreement to Deliver Scale & Efficiency13/03/2019View
  • Appendix 4E & Preliminary Final Report28/02/2019View
  • Major Brazilian Health Care Group Places Initial Pilot Order14/02/2019View
  • December Quarterly Activity Report & Appendix 4C31/01/2019View
  • Australian Distribution Agreement for 9000 HeraBEAT Units14/01/2019View
  • December Investor Presentation19/12/2018View
  • Becoming a substantial holder – Holley Pharmaceutical Group19/12/2018View
  • HeraMED Completes Over-Subscribed $6 Million IPO12/12/2018View
  • Becoming a substantial holder – Tal Slonim11/12/2018View
  • Becoming a substantial holder – David Groberman11/12/2018View
  • Initial Director’s Interest Notice – Tal Slonim11/12/2018View
  • Initial Director’s Interest Notice – Ronald Weinberger11/12/2018View
  • Initial Director’s Interest Notice – Doron Birger11/12/2018View
  • Initial Director’s Interest Notice – David Hinton11/12/2018View
  • Initial Director’s Interest Notice – David Groberman11/12/2018View
  • Statement of Confirmations10/12/2018View
  • Updated Statement of Commitments10/12/2018View
  • Voluntary Escrow10/12/2018View
  • Restricted Securities10/12/2018View
  • Updated Pro Forma Statement of Financial Position10/12/2018View
  • Capital Structure10/12/2018View
  • Securities Trading Policy10/12/2018View
  • Hera Med Ltd. Half Yearly Accounts to 30 June 201810/12/2018View
  • Hera Med Ltd. 2016 and 2017 Full Year Accounts10/12/2018View
  • Supplementary Prospectus10/12/2018View
  • Prospectus10/12/2018View
  • Constitution10/12/2018View
  • Appendix 1A and Information Form and Checklist10/12/2018View
  • Top 20 Holders10/12/2018View
  • Distribution Schedule10/12/2018View
  • ASX Notice – Admission to Official List10/12/2018View